WallStreetZenWallStreetZen

NASDAQ: ICCC
Immucell Corp Earnings Dates, Reports, Calls

OverviewEarnings
RevenueDividendOwnership
Immucell earnings were $787.4k for the trailing 12 months ending Jun 30, 2026, with -66.7% growth year over year. The latest ICCC earnings report on Jun 30, 2026 announced Q2 2026 earnings of $1.8M, down 5.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ICCC reported annual earnings of -$1.0M, with -51.8% growth. The next ICCC earnings date is Nov 12, 2026.

ICCC past earnings growth

How has ICCC's earnings growth performed historically?

Company
-66.67%
Industry
18.27%
Market
91.49%
ICCC's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ICCC's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

ICCC earnings history

Current Revenue
$30.7M
Current Earnings
$787.4k
Current Profit Margin
2.6%
ICCC's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

ICCC Return on Equity

Current Company
2.7%
Current Industry
-10.8%
Current Market
30.9%
ICCC's Return on Equity (2.7%)... subscribe to Premium to read more.
High Return on Equity Performance

ICCC Return on Assets

Current Company
1.8%
Current Industry
-10.7%
ICCC is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ICCC announces earnings.

ICCC Return on Capital Employed

Current Company
2.02%
Current Industry
-7.4%
ICCC has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ICCC vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ICCC$3.24M$787.37k+62.66%$0.07
NTRB-$6.76M-$6.96MN/A-$0.53
CGTX-$16.52M-$16.78MN/A-$0.17
NRXS-$7.47M-$8.45MN/A-$0.78
EQ-$17.91M-$18.01MN/A-$0.14
View Top Biotech Stocks

ICCC earnings dates

Next earnings date
Nov 12, 2026

Immucell Earnings Reports & History FAQ

What were Immucell's earnings last quarter?

On ICCC's earnings call on Aug 13, 2026, Immucell (NASDAQ: ICCC) reported Q2 2026 earnings per share (EPS) of $0.20, up 233.33% year over year. Total ICCC earnings for the quarter were $1.83 million. In the same quarter last year, Immucell's earnings per share (EPS) was $0.06.

If you're new to stock investing, here's how to buy Immucell stock.

When does Immucell report earnings?

The next ICCC earnings date is Nov 12, 2026. Add ICCC to your watchlist to be reminded of Immucell's next earnings date.

What was ICCC's earnings growth in the past year?

As of Immucell's earnings date in Aug 13, 2026, Immucell's earnings has grown -66.67% year over year. This is 84.94 percentage points lower than the US Biotechnology industry earnings growth rate of 18.27%. ICCC earnings in the past year totalled $787.37 thousand.

Is Immucell profitable or losing money?

As of the last Immucell earnings report, Immucell is currently profitable. Immucell's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $787.37 thousand, a 55.31% decrease year over year.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.